The Relationship Between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease and the Risk Involved.

NCT05479331 | Completed

• 1 other identifier: sarcopenia
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This study explores the risk factors for sarcopenia in patients with chronic kidney disease and the effects of sarcopenia on cardiovascular disease. Treatment of sarcopenia and cardiovascular complications provides a basis for improving the quality of life and survival of patients with chronic kidney disease.

Conditions

Sarcopenia; CKD; Cardiovascular Diseases

Outcome Measures

Primary Outcomes (2)

• Epicardial adipose tissue measured by ultrasound color doppler

  EAT is defined as a fat depot that exists on the surface of the myocardium,which plays a detrimental role in our health. EAT would be measured by ultrasound color doppler.

  the day when being recruited

• Intima-media thickness measured by ultrasound color doppler

  IMT of carotid arteries, as assessed noninvasively by carotid ultrasonography, is a useful measure of preclinical atherosclerosis. Carotid IMT has been found to predict future risk of cardiovascular disease.IMT would be measured by ultrasound color doppler.

  the day when being recruited

Secondary Outcomes (1)

• Baseline demographic, clinical and laboratory characteristics

  the day when being recruited

Study Arms (2)

sarcopenia

CKD patients with sarcopenia, meeting the following two criteria (1) male LTI (lean tissue index)\< 7.0 kg/m2, female LTI \< 5.7 kg/m2; (2) Male HGS)(handgrip strength \< 26 kg, female HGS \< 18 kg.

non-sarcopenia

CKD patients with non-sarcopenia

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with chronic kidney disease

You may qualify if:

• Patients presented by the Nephrology Center during August 2019 and March 2021
• Age 18-75 years;
• Patients with CKD2 or above (eGFR≤60 ml/(min 1.73m2)

You may not qualify if:

• There are contraindications to bioelectrical impedance spectroscopy (BIS) . examination, such as amputation, metal implants in the body, etc.;
• Complicated with other serious diseases, such as malignant tumors, cirrhosis, systemic infections, etc.

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Baoshan Site of Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200001, China

Location

MeSH Terms

Conditions

Sarcopenia; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Jiangzi Yuan, MD

  Baoshan Site of Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Chief Physician of Nephrology

Study Record Dates

• First Submitted: July 27, 2022
• First Posted: July 29, 2022
• Study Start: January 1, 2020
• Primary Completion: March 31, 2021
• Study Completion: December 31, 2021
• Last Updated: August 1, 2022

Record last verified: 2019-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)